

COVID-19
Community of
Practice for Ontario
Family Physicians

Dec 2, 2022

**Dr. Allison McGeer
Dr. Daniel Pepe
Dr. Liz Muggah**



***The latest on COVID, Influenza and
Respiratory Viruses***



Family & Community Medicine
UNIVERSITY OF TORONTO

Ontario College of
Family Physicians



The latest on COVID, Influenza and Respiratory Viruses

Moderator: Dr. Tara Kiran

Fidani Chair, Improvement and Innovation

Department of Family and Community Medicine, University of Toronto

Panelists:

- Dr. Allison McGeer, Toronto
- Dr. Daniel Pepe, London
- Dr. Liz Muggah, Ottawa

Co-hosts:

- Dr. Mekalai Kumanan, OCFP President

The COVID-19 Community of Practice for Ontario Family Physicians is a one-credit-per-hour Group Learning program that has been certified for up to a total of 32 credits.

Land Acknowledgement

We acknowledge that the lands on which we are hosting this meeting include the traditional territories of many nations.

The OCFP and DFCM recognizes that the many injustices experienced by the Indigenous Peoples of what we now call Canada continue to affect their health and well-being. The OCFP and DFCM respects that Indigenous people have rich cultural and traditional practices that have been known to improve health outcomes.

I invite all of us to reflect on the territories you are calling in from as we commit ourselves to gaining knowledge; forging a new, culturally safe relationship; and contributing to reconciliation.


New UNBC book focuses on Indigenous experiences in healthcare

The textbook includes critical theory, storytelling, poetry and art



[Hanna Petersen](#)

Nov 16, 2022 12:25 PM



A new textbook, which was compiled by a team of editors based at UNBC, features Indigenous voices and experiences regarding decolonization in healthcare.

UNBC's Dr. Margo Greenwood is one of the editors of the textbook. | NCCIH

<https://www.princegeorgecitizen.com/local-news/new-unbc-book-focuses-on-indigenous-experiences-in-healthcare-6113257>

Changing the way we work

A community of practice for family physicians during COVID-19

At the conclusion of this series participants will be able to:

- Identify the current best practices for delivery of primary care within the context of COVID-19 and how to incorporate into practice.
- Describe point-of-care resources and tools available to guide decision making and plan of care.
- Connect with a community of family physicians to identify practical solutions for their primary care practice under current conditions.

Disclosure of Financial Support

This CPD program has received in-kind support from the Ontario College of Family Physicians and the Department of Family and Community Medicine, University of Toronto in the form of logistical and promotional support.

Potential for conflict(s) of interest:

N/A

Mitigating Potential Bias

- The Scientific Planning Committee has full control over the choice of topics/speakers.
- Content has been developed according to the standards and expectations of the Mainpro+ certification program.
- The program content was reviewed by a three-member national/scientific planning committee.

Planning Committee: Dr. Tara Kiran (DFCM), Dr. Mekalai Kumanan (OCFP); Kimberly Moran (OCFP) and Mina Viscardi-Johnson (OCFP)

Previous webinars & related resources:

<https://www.dfcm.utoronto.ca/covid-19-community-practice/past-sessions>



Dr. Allison McGeer – Panelist

Infectious Disease Specialist, Mount Sinai Hospital



Dr. Daniel Pepe – Panelist

Twitter: @dpepe88

London Lambeth Medical Clinic



Dr. Liz Muggah – Panelist

Senior Clinical Advisor, Primary Care, Ontario Health
Family Physician, Bruyère Family Health Team



Dr. Mekalai Kumanan– Co-Host

Twitter: @MKumananMD

President, Ontario College of Family Physicians
Family Physician, Two Rivers Family Health Team
Chief of Family Medicine, Cambridge, ON

Speaker Disclosure

- Faculty Name: **Dr. Allison McGeer**
- Relationships with financial sponsors: Novavax, Medicago, Sanofi-Pasteur, GSK, Merck
 - Grants/Research Support: Sanofi-Pasteur, Pfizer
 - Speakers Bureau/Honoraria: Moderna, Pfizer, AstraZeneca, Novavax, Medicago, Sanofi-Pasteur, GSK, Merck
 - Others: N/A

- Faculty Name: **Dr. Daniel Pepe**
- Relationships with financial sponsors:
 - Grants/Research Support: N/A
 - Speakers Bureau/Honoraria: Ontario College of Family Physicians, London Health Sciences Centre
 - Others: N/A


- Faculty Name: **Dr. Liz Muggah**
- Relationships with financial sponsors:
 - Grants/Research Support: N/A
 - Speakers Bureau/Honoraria: N/A
 - Others: Ontario Health

Speaker Disclosure


- Faculty Name: **Dr. Mekalai Kumanan**
- Relationships with financial sponsors:
 - Grants/Research Support: N/A
 - Speakers Bureau/Honoraria: ECHO Chronic Pain and Rheumatology Advisory Board, Ontario College of Family Physicians
 - Others: N/A
- Faculty Name: **Dr. Tara Kiran**
- Relationships with financial sponsors:
 - Speakers Bureau/Honoraria: St. Michael's Hospital, University of Toronto, Health Quality Ontario (HQO), Canadian Institutes for Health Research (CIHR).Ontario College of Family Physicians (OCFP), Ontario Medical Association (OMA), Doctors of BC, Nova Scotia Health Authority, Osgoode Hall Law School, Centre for Quality Improvement and Patient Safety, Vancouver Physician Staff Association, University of Ottawa, Ontario Health, Canadian Medical Association, McMaster University, Queen's University, North American Primary Care Research Group.
 - Grants/Research Support: Canadian Institute for Health Research, Ministry of Health and Long-Term Care, St. Michael's Hospital Foundation, St. Michael's Hospital Medical Services Association, Women's College Hospital Academic and Medical Services Group Innovation Fund, University of Toronto, Health Quality Ontario, Ontario Ministry of Health, Gilead Sciences Inc., Staples Canada, Max Bell Foundation.

How to Participate


- All questions should be asked using the Q&A function at the bottom of your screen.



- Press the thumbs up button to upvote another guests questions. Upvote a question if you want to ask a similar question or want to see a guest's question go to the top and catch the panels attention.



- Please use the chat box for networking purposes only.





Dr. Daniel Pepe – Panelist

Twitter: @dpepe88

London Lambeth Medical Clinic



Dr. Allison McGeer – Panelist

Infectious Disease Specialist, Mount Sinai Hospital



Dr. Liz Muggah – Panelist

Senior Clinical Advisor, Primary Care, Ontario Health
Family Physician, Bruyère Family Health Team

Practical Primary Care

Dan Pepe, MD CCFP

Population Health Management Strategies

- Acute Care
- Chronic Disease
- Disease Prevention & Risk Reduction

Documentation, Self Management, Care Escalation

- Clinical Notes that document the encounter, provide education and a warm hand off in case of escalation

Assessment:

Plan:

1. Conservative Measures:

«●»

2. Pharmacologic Management:

«●»

3. Investigations/ Referrals:

«●»

4. Preventative Care:

«●»

«D.Pepe, MD» «C.Lin-Pepe, MD»

Assessment: Viral Illness NYD

Plan:

1. Conservative Measures:

I spent time discussing fever management today
we reviewed conservative measures including measure of temperature, ensuring hydration and avoiding dehydration
we discussed monitoring of adequate urine output
I also counselled on appropriate dosages of tylenol and advil given regularly in an alternating fashion to manage fever

2. Pharmacologic Management:

-I spent time discussing with the patient today the importance of fever management
- In particular we discussed using Tylenol (Acetaminophen) and Advil (Ibuprofen)
- We discussed the importance of alternating these medications and also to follow strict weight based dosing to ensure safety in medication administration

3. Investigations/ Referrals:

Today we discussed red flags and when to present back to clinic or seek care in the ER

- 1. Unable to drink fluids with signs of dehydration**
- 2. Persistent fever (Temperature > 38 degrees) that is not responding to regular doses of tylenol and advil**
- 3. Signs of working harder to breathe: chest pulling in under ribs, between ribs or tugging at the top of chest as reviewed today in office**

4. Preventative Care:

n/a

D.Pepe, MD

Assessment: Acute Bilateral AOM - Bacterial

Plan:

1. Conservative Measures:

Reviewed anatomy of ear including - outer, middle and inner ear
Time was taken to explain the physiology of hearing as well as drainage of the middle ear and eustachian tube function
The importance of ear wax including: anti-fungal, antimicrobial and anti-infective properties were reviewed
Eustachian tube dysfunction and treatment strategies also reviewed

2. Pharmacologic Management:

-I spent time discussing with the patient today the importance of fever management
- In particular we discussed using Tylenol (Acetaminophen) and Advil (Ibuprofen)
- We discussed the importance of alternating these medications and also to follow strict weight based dosing to ensure safety in medication administration

3. Investigations/ Referrals:

We discussed red flags and when to present back to clinic or to the ER.

- 1. Unable to drink fluids or signs of dehydration despite attempts to hydrate**
- 2. Persistent Fever (Temp > 38 degrees) not responding to adequate tylenol/ advil**
- 3. Sudden loss of hearing or significant drainage of fluid from one ear**
- 4. Pain behind ear, neck stiffness, worsening and not improving despite treatment**


4. Preventative Care:

n/a


D.Pepe, MD

Ontario COVID-19 waste-water surveillance

Province-Wide COVID-19 Wastewater Signal




COVID-19 Wastewater Signal - GTA





COVID-19


Variants, hospitalizations, deaths




XBB & XBB.1 still <1%



Distribution of positive specimens for respiratory viruses, PHOL, Nov 20-26, 2022





Distribution of positive specimens for respiratory viruses other than SARS-CoV-2, PHOL, Nov 20-26, 2022



Where are we in influenza season? (seasons usually 12-16 weeks)

VE against hospitalization (Chile)
49% (23%-67%)

<https://www.cdc.gov/mmwr/volumes/71/wr/mm7143a1.htm>



<https://www.canada.ca/en/public-health/services/surveillance/respiratory-virus-detections-canada.htm>

<https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/respiratory-pathogens-weekly>

Who should receive antiviral prophylaxis for influenza?

POST-EXPOSURE

- Those exposed in outbreaks in close facilities, with a fixed residential population
- *Note: For other exposures risk of illness is low enough that pre-emptive therapy (if symptoms develop) is preferred*

Consider PRE-EXPOSURE

- When vaccination contra-indicated or during 14 days post-vaccination
- When there is evidence of poor vaccine effectiveness

Who should receive antiviral treatment for influenza?

ANYONE

- At higher risk of complications of influenza
- Who has severe, complicated or progressive illness
- Who is hospitalized

Consider PRE-EXPOSURE

- When vaccination contra-indicated or during 14 days post-vaccination
- When there is evidence of poor vaccine effectiveness

Treating influenza

- Does this patient have influenza?
- If yes, do they need help controlling viral replication?
- How much do I need to worry about adverse effects?

Does this patient have influenza?

- Timing during season – at peak, 70% of “ILI” have influenza
- Fever – higher fever=more flu
 - “fever” in older adults =lower temp
- Early cough
- “Prostration”
- COVID-19 test negative
- Flu RAT positive

Do they need help controlling viral replication?

YES

- Higher fever
- Overall, increased severity
- Not improving after 3-4 days
- Immunocompromised
- Frail, multiple comorbidities

NO

- Improving

Will this patient have adverse events?

- *Nausea/vomiting most common (younger, female); headache ~1%*
- *Always take oseltamivir with snack/meal (especially first dose)*
- *Antiviral resistance is not an issue, because oseltamivir is ONLY active against influenza)*

Additional Updates: Limited Use Code for Oseltamivir/Tamiflu (effective Nov 30)

- Aligned with PHO 2022 **criteria for treatment of individuals at high risk*** of complications from influenza with either laboratory-confirmed or illness consistent with influenza A or B
- High risk ie: <5yr , >65 yr, pregnant/ 4wks post-partum, chronic illnesses, Indigenous, living in congregate setting
- **PHO Influenza Antiviral Treatment (2022)** <https://www.publichealthontario.ca/-/media/Documents/A/2022/antiviral-medications-seasonal-influenza-2022-23.pdf?rev=c253cd2289df4141a2107e79c4e01795&la=fr>
- **MOH ODB Update (Nov 2022 - LU code effective for the 2022–2023 influenza season only)** https://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/summary_edition43_20221123.pdf

Risk factors for Omicron BA.1/BA.2 infection

Variable		Multivariable Cox Regression Results	
		Hazard Ratio (95% CI)	P-value
Group	No early infection	Reference	0.005
	Early infection	0.56 (0.37-0.84)	
Age group	18-49 years	Reference	0.001
	50-64 years	0.64 (0.42-0.97)	
	≥65 years	0.35 (0.20-0.61)	
Covid-19 Vaccination Status as of 15/12/2021	Not vaccinated	Reference	<0.001
	Received ≥2 doses, most recent <182 days ago	0.44 (0.21-0.94)	
	Received ≥2 doses, most recent ≥182 days ago	0.98 (0.42-2.26)	
Covid-19 Vaccine during BA.1/BA.2 period	No vaccine doses received	Reference	0.006
	Received one dose		
	At 7-89 days after dose	0.42 (0.24-0.73)	
	At ≥90 days after dose	1.14 (0.59-2.22)	

CAC/ILI Clinics - Spread and Scale

OCFP/DFCM Community of Practice

DR. ELIZABETH MUGGAH | DECEMBER 2 2022

Background

- Goal is to support pandemic response and permit other essential Primary Care services continue in other settings by building upon existing Clinical Assessment Centres (CAC)/Assessment Centres (AC)
- Expand care to all febrile respiratory illnesses and pediatric patients
- Population-based planning with prioritization for communities with higher needs/ED use and focus on care of unattached patients
- Focus on partnering with primary care – either expanding existing CACs clinics partnered with PC practices and/or opportunity to add new CACs clinics based in primary care

Elements



Clinic care pathways to support testing, clinical assessment and treatment of COVID –19 and febrile respiratory illness



Primary care maintains continuity of care and commitment to shared care through information-sharing with patient's own primary care provider



Dedicated clinical space that support the ongoing response to the pandemic while recovery and deferred care is addressed in other settings




Common branding supports the right care in the right place at the right time with a consistent model of care



Population health approach

Site Locations and Access

Current CAC/AC Sites



* Dynamic expansion occurring; sites subject to change



Location Information

<https://www.ontario.ca/assessment-centre-locations>

Ontario français

[Home](#) > [COVID-19](#) > [Testing](#)

Last updated: November 30, 2022

COVID-19 testing locations and clinical assessment centres

Find your closest location to get a COVID-19 test or clinical assessment.

Free rapid test kits

Ontario is distributing free rapid antigen tests through pharmacy and grocery locations across the province, as well as through community partners in vulnerable communities.

[Learn about the free rapid test kit program and where to find a location.](#)

Clinical assessment centres

On this page, you can search for clinical assessment centres (where you can get assessed, tested, and provided treatment options for COVID-19).

[Get more information on clinical assessment centres and find out if you're eligible for COVID-19 antiviral treatment.](#)

Before you go

[Find out if you should go for a test or clinical assessment before searching for a location.](#)

Family Doctor Tips on Caring for Children with Respiratory Symptoms

Most respiratory illness in children, including colds, influenza, RSV (respiratory syncytial virus) and COVID-19 can be managed at home without the need for prescription medications. However, in some cases, it is important to seek medical care.

Below, family doctors share tips on how to decide when to seek care for a respiratory illness and how to support your child at home.

Call your family doctor if your child:

- Has a fever lasting 72 hours or longer.
- Has a fever that went away for a day or longer (without fever medication) and then came back.
- Is unusually irritable and won't stop fussing, even after treating their fever.
- Has an earache lasting more than 48 hours.
- Is not eating or drinking. Note that it's normal to eat and drink less when sick. Liquids are more important than food.
- Has special needs that make caring for them more difficult.

As a parent or guardian, you know your child best. If you feel your child needs to be seen by a family doctor, please reach out for help.



Not sure what to do? Health Connect Ontario has a **symptom checker** and the option to **chat live with a nurse**. You can also call 811 to speak with a nurse, available 24 hours a day.

Call 911 or go to the emergency department when:

- You are worried that your child is seriously ill.
- Your infant, younger than three months old, has a fever.
- Your child is struggling to breathe or is breathing faster than normal.
- You are concerned that your child is at risk of dehydration or is dehydrated.

These are only some examples of when to seek emergency care. Children's Hospital of Eastern Ontario (CHEO) has more information to **help decide if your child needs emergency care**.

For more information specific to COVID-19 and children, including rare complications, see **My Child Has COVID. What Should I Know?** in the **Confused About COVID** series.

Helping your child at home

- **Fever:** Treat fever or pain with over-the-counter medicines such as acetaminophen or ibuprofen if your child can take it. As a reminder, Aspirin or products containing acetylsalicylic acid (ASA) are not recommended for children.




Call your family doctor or pharmacist for advice if you are having difficulty accessing over-the-counter medicines. Information from the Canadian Pediatric Society outlines **how to take a child's temperature** and what to do if they have a fever. Here is a video on **managing fever in a child** from the U.K.'s National Health Service.

- **Red eyes and discharge:** These symptoms almost always go away on their own, without antibiotic drops or other medication. Warm compresses and artificial tears can help reduce discomfort.
- **Stuffy and runny nose:** Try saline rinsing sprays, a humidifier or a nasal aspirator.
- **Earache:** If you notice your child tugging on their ear, they may have an earache. Get assessed if your child's earache lasts more than 48-72 hours, if there is discharge from the ear or they have had more than 2-3 ear infections in the last year.
- **Cough:** Treat a cough with a humidifier or the steam from a shower. If the cough sounds like a bark, cool outside air may help. If your child is at least one year old, you can give them 1-2 teaspoons of honey in the evening.
- **Fluids:** Make sure your child gets enough fluids, including water, soups, fruit juice or even popsicles. Breastmilk/formula is enough for young babies who do not drink other fluids.

Tips to stay healthy and prevent illness

- Wear a mask (and have your child wear a mask) when in crowded, public indoor spaces.
- Wash your hands often and well; use hand sanitizer when washing is not possible.
- Cough and sneeze into your elbow instead of your hands.
- Stay home and keep your child home when they are sick, especially in the first couple of days when most infectious.
- Get the flu shot and keep COVID-19 doses up to date.




Download Family Doctor Tips in PDF format:




The OCFP thanks Dr. Kate Miller and Norfolk Family Medical for the blog post which inspired this information.

Common Respiratory Illness in Children

Tip Sheet for Family Doctors

Common Respiratory Illnesses in Children: Tip Sheet for Family Doctors					
					
	Causes	Diagnosis	Signs	Management	Red Flags
URTI (upper respiratory tract infection)	Viral	Clinical – NPS not necessary	Sneezy, stuffy nose	Supportive treatment No role for oral/inhaled/intranasal steroids or antibiotics	
Croup	Acute-onset upper airway obstruction secondary to viral infection	Clinical – chest/lateral neck x-ray not necessary	Barky cough with or without stridor Usually ages 6 months to 3 years	Oral dexamethasone 0.6 mg/kg x 1 No antibiotics	Rule out: bacterial tracheitis, epiglottitis, retropharyngeal abscess, anaphylaxis, foreign body aspiration Note: toxic appearance, drooling, dysphasia is NOT croup ! Emergency Department if: <ul style="list-style-type: none"> • Toxic-appearing • Stridor or WoB (work of breathing) at rest, biphasic stridor • Drooling or dysphagia • Lethargy or distress
Bronchiolitis (viral lower respiratory tract infection)	Can be caused by any virus, including RSV	Clinical – x-rays only if severe or alternate diagnosis suspected; labs/NPS not necessary	Low-grade fever, cough and rhinorrhea, wheeze, crackles with or without respiratory distress Usually <2 years of age	Supportive treatment, including hydration, anti-pyretics. Nasal suctioning to support feeds. No evidence for Ventolin, steroids, antibiotics or antivirals	Rule out: asthma, pneumonia, foreign body aspiration Higher risk for severe disease: <ul style="list-style-type: none"> • Infants born prematurely (<35 weeks gestation) • <3 months of age at presentation • Hemodynamically significant cardiopulmonary disease • Immunodeficiency ! Emergency Department if concerns about: <ul style="list-style-type: none"> • Respiratory rate • WoB (work of breathing) • O2 saturations • Mental status • Apneas • Hydration

1/3

Common Respiratory Illnesses in Children: Tip Sheet for Family Doctors					
					
	Causes	Diagnosis	Signs	Management	Red Flags
Bacterial pneumonia	Bacterial	Chest x-ray – focal lobar consolidation or worse (parapneumonic effusion, empyema, abscess, etc.). Atypical pathogens can have bilateral infiltrates NPS, labs not indicated for outpatients No repeat chest x-ray after illness if clinical improvement	High-grade fever, cough, focal crackles (NOT wheeze), appears "sicker", with or without respiratory distress	Amoxicillin 90 mg/kg/day divided TID x 5 days for uncomplicated community-acquired bacterial pneumonia. Note: Atypicals – treatment with macrolides is controversial, as it will typically resolve without treatment. Treatment with macrolides may help with chronic cough.	! Emergency Department if concerns about: <ul style="list-style-type: none"> • Respiratory rate • WoB (work of breathing) • O2 saturations • Mental status • Apneas • Hydration
Asthma	Personal or family history of atopy Common triggers for exacerbations: infection, physical activity, allergens, cold air, pollution, poor compliance to asthma treatments	Clinical – chest x-ray not required PFTs (pulmonary function tests) recommended for older children	Recurrent wheeze that is responsive to bronchodilator treatment	Ventolin, with or without inhaled corticosteroids (ICS) depending on severity, and oral steroids if acute exacerbation Exacerbation: <ul style="list-style-type: none"> • Ventolin 2-4 puffs q4h PRN (or ICS-Long acting beta agonist (LABA) for teens) – use regularly q4h during an exacerbation. • Oral corticosteroids: dexamethasone 0.3-0.6 mg/kg x 1-2 days; prednisolone 1 mg/kg x 3-5 days. • No evidence for increasing ICS during illness or short-term; no evidence for intermittent use of ICS. Controller therapy: <ul style="list-style-type: none"> • Avoid triggers and manage comorbidities. • Have written asthma action plan. • Use aerochambers for metered dose inhalers (MDIs) and confirm technique. • Ensure compliance in ICS use (4-6 weeks for any effect; monitor for side effects). 	

2/3

https://www.ontariofamilyphysicians.ca/respiratory-infections/ocfp_respillnessesinchildrenfptipsheet.pdf

The OCFP thanks Dr. Tasha Stoltz for her COVID-19 Community of Practice presentation which was the basis for this resource.

Managing patients with respiratory symptoms in office

RESOURCES: December 2022

- **Respiratory Infections Resources for Family Physicians**
<https://www.ontariofamilyphysicians.ca/respiratory-infections>
- **Fall update to patients – script** (incl. flu vaccination, COVID vaccines, and when to seek care)
<https://www.ontariofamilyphysicians.ca/tools-resources/covid-19-resources/clinical-care-office-readiness/fall-update-to-patients.pdf>
- **IPAC Summary for Community Practices – updated**
<https://www.ontariofamilyphysicians.ca/tools-resources/covid-19-resources/clinical-care-office-readiness/ipac-summary.pdf>
- **Managing patients with respiratory symptoms in office – overview**
<https://www.ontariofamilyphysicians.ca/tools-resources/covid-19-resources/clinical-care-office-readiness/covid-screening-tool.pdf>
- **My child has COVID. What should I do? – updated** (*Confused About COVID* series)
<https://rebrand.ly/Child-has-COVID>

Appendix C: Flow Diagram for COVID-19 Fall Booster Vaccination

When to get a fall COVID-19 booster

Use the chart below if you have completed your primary series and are aged 5 and older.

Start

Has it been at least
6 months since:

- your last COVID-19 vaccine dose, or
- you tested positive for COVID-19?

Yes

Get your booster now

Protect yourself during respiratory illness season and before cool weather leads to more time indoors.

No

Do any of the following
apply to you?

- Aged 65 or older
- Resident of long term care, retirement home, or other congregate care setting
- Aged 12 or older and moderately to severely immunocompromised¹ or with an underlying medical condition²
- Health care worker
- Pregnant
- Adult First Nations, Inuit, or Métis individual or household member
- Adult in racialized and/or marginalized community disproportionately affected by COVID-19

Yes

Get your booster 3 months after your last dose or last COVID-19 infection

You are at high risk of severe outcomes and are **strongly recommended to get your booster dose at a shorter interval** to protect yourself during respiratory illness season and before cool weather leads to more time indoors.

No

Get your booster 6 months after your last dose or last COVID-19 infection

You are not at high risk of severe outcomes. Longer intervals between vaccines may result in a better immune response and higher vaccine effectiveness.

Notes

1. If you are immunocompromised, talk to your health care provider about the timing of your booster.

2. May include: heart, kidney, or lung conditions, diabetes and other metabolic conditions, cancer, anemia or hemoglobinopathy, neurologic or neurodevelopmental conditions, a Body Mass Index (BMI) of 40 and over.

All vaccines available in Ontario are approved by Health Canada and are safe, effective, and are the best way to stay protected from COVID-19 and its variants.

COVID-19 Vaccine Guidance (Version 3.1, November 7, 2022, pg 25)

https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19_vaccine_administration.pdf

Decision Aid only pdf :

<https://www.ontariofamilyphysicians.ca/tools-resources/covid-19-resources/covid-19-vaccines/when-you-should-get-a-booster-dose-flowchart.pdf>

Booster dose eligibility checker – online tool:



<https://www.ontario.ca/vaccine-eligibility/>

OMA Tools

Virtual Care Billing: a Visual Guide

A visual guide explaining the new permanent billing codes for virtual care that went into effect December 1st.

- <https://www.oma.org/uploadedfiles/oma/media/members/membermappedpdfs/negotiations/psa/oma-virtual-care-codes-visual-guide.pdf/>



OMA Tools

Influenza Quick Reference Guide

Information on which of the six publicly funded vaccine products to administer based on the patient's age.

- <https://www.oma.org/uploadedfiles/oma/media/member/membermappedpdfs/practice-professional-support/coronavirus/oma-covid-19-vaccine-reference-tool.pdf/>



Ontario 2022-2023 Influenza Quick Reference Guide

Publicly funded vaccines for the 2022-2023 season

Below are the age-specific vaccine products publicly funded in Ontario for the 2022-2023 season.

Age Group	QIV*	QIV*	QIV*	QIV-HD**	TIV-adj***
	FluLaval Tetra, GSK (egg-based) 0.5mL dose	Fluzone® Quadrivalent, Sanofi Pasteur (egg-based) 0.5mL dose	Afluria® Tetra, Seqirus (egg-based) 0.5mL dose	Fluzone® High-Dose Quadrivalent, Sanofi Pasteur (egg-based) 0.7mL dose	Fluad®, Seqirus (egg-based) 0.5mL dose
65 years and older	✓	✓	✓	✓ Preferred	✓ Preferred
5 to 64 years	✓	✓	✓		
6 months to 4 years	✓	✓			

Other flu vaccines that are not publicly funded for the 2022-2023 season, including FluMist® (intranasal spray), Flucelvax® (cell-based vaccine) and Supemtek™ (recombinant protein vaccine) may be purchased by patients at a pharmacy.

COVID-19 Vaccine Reference Tool

Reference tool on COVID-19 vaccines to help physicians determine the right vaccine dose and interval for patients based on age and immune status.

- <https://www.oma.org/uploadedfiles/oma/media/member/membermappedpdfs/practice-professional-support/coronavirus/oma-covid-19-vaccine-reference-tool.pdf/>



COVID-19 Vaccine Reference Tool

This content is reflective of Ontario's guidance on COVID-19 vaccination

General population under 18 years

Primary Series

Eligible groups	Vaccine Product	Number of doses	Dosage	Interval
Ages 6 months – 4 years	Pfizer	3	Maroon Cap: 0.2mL (3mcg mRNA)	Between Dose 1 and 2: Reco: 2 months/56 days Min. 21 days Between Dose 2 and 3: Reco: 2 months/56 days Min. 2 months/56 days
	Moderna	2	Royal Blue Cap: 0.25mL (25mcg mRNA)	Reco: 2 months/56 days Min. 28 days
Age 5 years	★ Pfizer	2	Orange Cap: 0.2mL (10mcg mRNA)	Reco: 2 months/56 days Min. 28 days
	Moderna		Royal Blue Cap: 0.25mL (25mcg mRNA)	
Ages 6 – 11 years	★ Pfizer	2	Orange Cap: 0.2mL (10mcg mRNA)	Reco: 2 months/56 days Min. 28 days
	Moderna		Red Cap: 0.25mL (50mcg mRNA) Royal Blue Cap: 0.5mL (50mcg mRNA)	
Ages 12 – 17 years	★ Pfizer	2	Purple or Grey Cap: 0.3mL (30mcg mRNA)	Reco: 2 months/56 days Min. 28 days
	Moderna		Red Cap: 0.5mL (100mcg mRNA)	

- Pfizer and Moderna vaccine products are authorized for different pediatric age groups:
 - Pfizer (3mcg): 6 months – 4 years
 - Moderna (25 mcg): 6 months – 5 years
 - Pfizer (10mcg): 5 – 11 years
 - Moderna (50 mcg): 6 – 11 years

- Preferential recommendation:
 - There is no preferred vaccine product for children aged 6 months to 4 years.
 - Pfizer is preferred over Moderna in individuals ages 5-17 years because of an observed increase in reports of myocarditis/pericarditis with the Moderna vaccine among adolescents and young adults.

Reco = recommended interval Min = minimum interval ★ = preferential recommendation

OMA Tools

Personal Protective Equipment

Visual of government recommendations for PPE use in the community practice setting during the COVID-19 pandemic.

- <https://www.oma.org/uploadedfiles/oma/media/member/membermappedpdfs/practice-professional-support/patient-care/oma-guidance-ppe-community-practices-poster.pdf/>

OMA Ontario Medical Association

What Personal Protective Equipment to Use in your Community Practice

COVID-19 Recommendations for Health Care Workers and Staff

In all patient care areas	Caring for or within 2m of patients who screen negative for COVID-19	Caring for or within 2m of patients who screen positive for COVID-19	Performing an aerosol-generating procedure
In non-patient care areas within 2m of others*		Screening patients without a plexiglass barrier	
<ul style="list-style-type: none"> • surgical / procedure mask 	<ul style="list-style-type: none"> • surgical / procedure mask • eye protection is recommended during periods of high transmission and otherwise based on Routine Practices** • gloves in select instances when giving vaccines*** 	<ul style="list-style-type: none"> • N95 respirator (alternatives to a fit-tested, seal-checked N95 are a non-fit tested N95 or respirator or a well-fitting surgical mask) • eye protection • gloves • gown 	<ul style="list-style-type: none"> • N95 respirator (fit-tested, seal-checked) • eye protection • gloves • gown • airborne infection isolation room or room with a closed door
		EYE PROTECTION OPTIONS 	

* In periods of low transmission risk, masking of health-care workers for source control in non-clinical areas may be optional. Low transmission risk occurs when hospitalizations and ICU admissions are low and stable and community transmission is low.
 ** High transmission risk occurs when hospitalizations and ICU admissions are high and/or on an upward trajectory and community transmission is high and increasing.
 *** Gloves should be considered when administering vaccines as per the Canadian Immunization Guide. In most cases gloves do not need to be worn except when the skin on the vaccine provider's hands is not intact, administering intranasal or oral vaccines due to the increased likelihood of coming into contact with a patient's mucous membranes and body fluids, and/or administering Bacille Calmette-Guérin (BCG) vaccine.

Public Health Ontario, Interim Infection Prevention and Control Measures based on COVID-19 Transmission Risks in Health Care Settings
 Public Health Ontario, Interim IPC Recommendations for Use of Personal Protective Equipment for Care of Individuals with Suspected or Confirmed COVID-19
 Public Health Ontario, Frequently Asked Questions for Interim IPC Measures based on COVID-19 Transmission Risks in Health Care Settings
 v5 27-Jun-22

oma.org

Testing in Office

An overview guide on providing PCR testing in community-based practices, including office preparation, test collection, submission, results and billing.

- <https://www.oma.org/uploadedfiles/oma/media/member/membermappedpdfs/practice-professional-support/coronavirus/offering-lab-based-pcr-testing-for-covid-19.pdf/>

OMA Ontario Medical Association

Offering lab-based PCR testing for COVID-19 in your office

A guide for community-based practices

Lab-based polymerase chain reaction (PCR) tests are the gold standard used to diagnose or rule out COVID-19. These are the same type of tests that are offered in assessment centres; the specimen is collected in your office and then sent to a lab to run the test.

Providing lab-based PCR tests in your practice is optional. If you do not have capacity to test in your office, refer the patient to a local [testing site](#) or the Emergency Department, as appropriate based on your clinical assessment.

Who to test

Groups eligible for publicly funded PCR tests are outlined in the Ministry of Health's [COVID-19 Provincial Testing Guidance](#).

They include:

- Select symptomatic patients, including patients 70+, patients 60+ with less than three doses of COVID-19 vaccine, immunocompromised patients, and patients 18+ with less than three doses of vaccine and at least one risk factor (e.g. obesity, diabetes, etc.)
- Individuals being admitted or transferred to or from a hospital or congregate living setting

Did you know?

Rapid molecular tests can be used to diagnose COVID-19 within 30 minutes. These tests can only be used in select scenarios and require additional administrative work to report the results.

Rapid antigen tests can also now be used to diagnose COVID-19. A positive result on a rapid antigen test is considered a confirmed case of COVID-19. However, a single negative result cannot be used to rule out COVID-19.

Preparing to test

Specimen collection supplies

Specimens can be collected using several different types of kits: nasopharyngeal, deep nasal/nasolabial or saliva. For information on the different types of specimen collection kits, please refer to Public Health Ontario's (PHO's) [COVID-19 PCR Collection Kits](#) page.

Free swab kits are available to [order online from eHealth Ontario](#). Indicate the type of swab kits that you would like to order and include your contact information, desired quantity, and expected delivery date. If you have any questions during the ordering process, contact covid19testing@ontariohealth.ca.

Personal Protective Equipment (PPE) and isolation requirements

To test someone with suspected COVID-19, Droplet/Contact precautions are required, including hand hygiene prior to donning and after doffing PPE.

PPE required to collect a specimen

- N95 respirator*
- eye protection (face shield, goggles, or mask with visor)
- gloves
- gown

* If a fit-tested, seal-checked N95 respirator is not available, you can use a non-fit tested N95 respirator, or a well-fitting surgical mask.

OMA Ontario Medical Association | Offering lab-based PCR testing for COVID-19 in your office | v5 4-May-22

oma.org

CareCanvas

Better Care, Made Easier

A NEW TOOL TO SUPPORT PRACTICE IMPROVEMENT

An interactive web-based dashboard that summarizes clinical information from your practice EMR.



- Designed for family physicians and primary care teams
- Three dashboards will be available: one for physicians, one for clinics, and one for Ontario Health Teams
- More than 15 quality of care measures
- Makes it easy for physicians to identify patients who need follow-up and for clinics to meet reporting requirements
- Private, secure, and available at no cost
- Any physician who is a member of Telus Practice Solutions, Accuro, or Oscar EMR can contribute data to UTOPIAN or POPLAR
- The physician dashboard will be available to existing UTOPIAN contributors in November, with plans to expand the program to all of POPLAR in early 2023

Visit: <https://www.carecanvas.ca>



Family & Community Medicine
UNIVERSITY OF TORONTO

The dashboard was developed by the University of Toronto and POPLAR



Fully- virtual, including two live-streamed days on **January, 27 and 28, 2023** plus **20 on-demand sessions**.

Registration is now open

Join us as we discuss important topics from **culturally inclusive care** to the anticipated **impacts of an ageing family physician workforce**.

What to expect:

- Keynotes, talks and panel discussions from **thought leaders** and **clinical experts** on the topics that matter most.
- A unique learning experience with the flexibility to **join live** or **learn later**, with conference content available until July 31, 2023.
- An opportunity to earn up to **40 Mainpro+ credits**.

**This year's
keynote speakers
include:**

Lieutenant-General (ret) The Honourable Roméo Dallaire

Global humanitarian, PTSD and mental health advocate

Dr. Mekalai Kumanan

President, Ontario College of Family Physicians

Dr. Aika Lafontaine

President, Canadian Medical Association

Dr. Robert Varnam

Leadership coach and ex-national director Primary Care Improvement, NHS England

Treating **mental health, substance use disorders and chronic pain** in an integrated way has become more demanding and complex - now more than ever.

Practising Well is here to help!


Join upcoming [Community of Practice](#) sessions

- December 14, 2022 – Addressing overwhelm: Self compassion & setting boundaries
- January 18, 2022 – Physician disability
- February 22, 2022 – Mental health and trauma
- March 22, 2022 – Complexity in medicine



Participate in 1:1 or small group learning through [Peer Connect](#)

- Share your experience with mental health, substance use disorders and/or chronic pain with your colleagues as a [Peer Guide](#).
- Earn free Mainpro+ credits, build on your existing skills and achieve your learning goals in collaborative space as a [Peer Learner](#).



Continue your learning journey using the [Information Exchange](#)

- Access [clinical tools and resources](#) to help you in your practice.
- Find [other learning opportunities](#) through OCFP and other organizations.



Questions?

Webinar recording and curated Q&A will be posted soon

<https://www.dfcu.utoronto.ca/covid-19-community-practice/past-sessions>

Our next Community of Practice: December 16, 2022

Contact us: ocfpcme@ocfp.on.ca

Visit: <https://www.ontariofamilyphysicians.ca/tools-resources/covid-19-resources>

The COVID-19 Community of Practice for Ontario Family Physicians is a one-credit-per-hour Group Learning program that has been certified for up to a total of 32 credits..

Post session survey will be emailed to you. Mainpro+ credits will be entered for you with the information you provided during registration.